We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

SCOT Scleroderma Treatment Alternative Registry (STAR Registry)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00860548
First Posted: March 12, 2009
Last Update Posted: April 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
March 11, 2009
March 12, 2009
April 5, 2017
June 2005
March 2016   (Final data collection date for primary outcome measure)
Event-free survival (EFS) [ Time Frame: 44 months after subject enrollment ]

The events will be defined as any one of the following:

  • Death.
  • Respiratory failure defined as the need for supplementary oxygen; or
  • Renal failure, as defined by chronic dialysis > 6 months or renal transplantation.
Death, renal failure requiring dialysis, and pulmonary compromise requiring oxygen, pulmonary hypertension requiring treatment. [ Time Frame: Throughout study ]
Complete list of historical versions of study NCT00860548 on ClinicalTrials.gov Archive Site
  • Functional status as determined by the Modified Scleroderma Health Assessment Questionnaire (m-HAQ/S-HAQ) [ Time Frame: 44 months after subject enrollment ]
  • Mortality due to any cause [ Time Frame: 44 months after subject enrollment ]
  • Medical therapies and procedures (including hospitalizations) [ Time Frame: 44 months after subject enrollment ]
  • Diagnosis and treatment for pulmonary hypertension [ Time Frame: 44 months after subject enrollment ]
  • Need for hyperalimentation [ Time Frame: 44 months after subject enrollment ]
  • Amputation whether surgical or auto-amputation [ Time Frame: 44 months after subject enrollment ]
  • Hospitalization or surgery [ Time Frame: 44 months after subject enrollment ]
Medical therapies and procedures (including hospitalizations), scleroderma renal crisis, and functional status as determined by the modified Scleroderma Health Assessment Questionnaire [ Time Frame: Throughout study ]
Not Provided
Not Provided
 
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)

The Scleroderma Cyclophosphamide Or Transplant (SCOT) Trial is a Phase II/III interventional trial comparing two treatments for early, severe scleroderma. These two interventions are high dose immunosuppressive therapy followed by autologous stem cell transplantation and monthly high dose pulse cyclophosphamide (the later for 12 doses). While standard of care might be considered the optimal control arm for a trial such as this one, no such standard of care is available for the population of scleroderma patients defined by the eligibility criteria for this trial. The rheumatologists on the protocol team believe that the SCOT cyclophosphamide regimen represents the best control arm for this study. However, given concerns over use of a treatment arm as a control that has not been established as a standard of care, this registry was established. The registry will be a prospective, observational study of subjects with severe systemic sclerosis (SSc) who are eligible to participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study but are denied insurance coverage or decline to participate prior to randomization. Subjects will be accrued over the same period as the SCOT study. Subjects will follow the course of treatment prescribed by their treating physician with no interference from the registry.

The primary purpose of this study is to document the disease course and outcome in a group of participants who are eligible for the SCOT study, but declined to participate, in order to determine whether their outcome is better, worse, or no different than those who participate in the treatment phase of the trial.

For multiple reasons, the SCOT investigators and the sponsor of the SCOT trial, the Division of Allergy, Immunology, and Transplantation (DAIT) of the National Institute of Allergy and Infectious Diseases (NIAID), determined that it is important to track the course of a 'matched' group of patients, who are not exposed to these treatments but receive currently available therapy in the community. First, such a group will provide information to determine if the SCOT entry criteria do indeed identify these high-risk individuals. More importantly, such a group of patients is likely to be treated with a variety of medical regimens, including some immunosuppressive therapy with cyclophosphamide or other immunosuppressive agents that may modify the natural history of the disease. In evaluating the relative efficacy of the two treatment regimens, it will be important to assess whether outcomes in the subjects treated under the SCOT protocol have outcome profiles that differ from those associated with the matched group of patients treated in the community. One readily available group that meets these criteria are those individuals who are otherwise eligible for the SCOT trial but fail to be randomized because they either decline to participate or are denied insurance coverage to receive the SCOT treatment regimens.

The duration of this trial is 44 months. Participants will be enrolled over the same period as the SCOT trial. Participants will follow the course of treatment prescribed by their treating physician with no interference from the registry. All participant contact, including obtainment of informed consent and telephone interview regarding outcome measurements will be performed by SCOT study personnel at the University of Texas, Houston (one of the SCOT transplant centers). Participants will be contacted by phone every 3 months to determine vital status, record medical and other therapy, and administer the modified Scleroderma Health Assessment Questionnaire (S-HAQ). Medical records will be obtained to verify self-reported medical events.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participants with severe systemic sclerosis who are eligible for the SCOT study, but either decline to participate or are denied insurance coverage, prior to randomization will be invited to participate in this registry.
  • Scleroderma, Systemic
  • Sclerosis
Drug: currently available therapy in the community
Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • No additional inclusion criteria

Exclusion Criteria:

  • No additional exclusion criteria
Sexes Eligible for Study: All
18 Years to 69 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00860548
DAIT SCSSc-02
SCOT
Yes
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Maureen Mayes, MD, MPH The University of Texas Health Science Center, Houston
Study Chair: Daniel Furst, MD UCLA Medical School
Study Chair: Peter McSweeney, MD Blood and Marrow Transplant Program, Presbyterian/St. Luke's Medical Center, Rocky Mountain Cancer Center
Study Chair: Leslie J. Crofford, MD University of Michigan
Study Chair: Richard Nash, MD Fred Hutchinson Cancer Research Center
Study Chair: Keith Sullivan, MD Division of Cellular Therapy, Duke University
National Institute of Allergy and Infectious Diseases (NIAID)
April 2017